全球首个偏向型GLP-1减重数据登陆ADA并发表于柳叶刀子刊

Core Insights - The global first application for a biased GLP-1 receptor agonist, Ecnoglutide, has been reported at the 85th American Diabetes Association (ADA) conference and published in The Lancet Diabetes & Endocrinology, marking a significant advancement in China's clinical research in this field [1][2] - Ecnoglutide is a novel long-acting GLP-1 receptor agonist that activates cAMP signaling, enhancing efficacy while reducing side effects, thus validating the theory proposed by Nobel laureate Bob Lefkowitz regarding the efficiency of biased GLP-1 [1] Industry Impact - The early market entry of domestically developed GLP-1 drugs like Ecnoglutide could disrupt the current market dominated by imported original drugs, providing new treatment options for global metabolic disease patients [2] - Obesity has become a major public health issue in China, with 14.1% of the population classified as obese and 34.8% as overweight, highlighting the urgent need for effective weight loss solutions [2] Product Development - Ecnoglutide's weight loss-related indications have entered the listing application stage, indicating progress towards market availability [3]